Gadobutrol Patent Expiration
Gadobutrol is Used for enhancing images in magnetic resonance imaging procedures. It was first introduced by Bayer Healthcare Pharmaceuticals Inc
Gadobutrol Patents
Given below is the list of patents protecting Gadobutrol, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Gadavist | US5980864 | 1,4,7,10-tetraazacyclododecane butyltriols, processes for their production and pharmaceutical agents containing them |
Nov 09, 2021
(Expired) | Bayer Hlthcare |
| Gadavist | US5980864 | 1,4,7,10-tetraazacyclododecane butyltriols, processes for their production and pharmaceutical agents containing them |
Nov 09, 2016
(Expired) | Bayer Hlthcare |
Gadobutrol's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Gadobutrol:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
